• 한국식생활문화학회지
• /
• 제5권1호
• /
• pp.169-180
• /
• 1990

MNNG 투여에 의한 백서 위십이지장암 발생에 있어서 우유의 영향을 조사하고 그 원인을 분석키 위해 조직학적 및 혈청학적 분석을 시도하였다. 실험군은 생후 8주 전후의 Sprague-Dawley 백서 136마리로서 일반사료만 준 대조군 20마리(제 1군)와 6% 우유사료만 준 군 20마리(제 2군), MNNG$(100\;{\mu}g/ml)$ 투여군 24마리(제 3군), MNNG 및 6% 우유사료군 24마리(제 4군), MNNG 및 13% 우유사료군 24마리(제 5군), MNNG 및 26% 우유사료군 24마리(제 6군)로 분류한 후 군별에 따라 28주간 발암제 및 우유사료를 투여하고 실험시작 40주째 생존한 109마리에 대해 다음과 같은 결과를 얻었다. 1. MNNG 단독 투여로 실험시작 12주 이후의 성장에 영향을 주었으나(p<0.01) 가역적이었고 생존에 미치는 영향은 없었다. 2. 위암발생은 대조군, 우유사료군에서 없었고 제 3군 25%, 제 4군 36.8%, 제 5군 27.8%, 제 6군 14.3%로 우유사료군에서 우유농도 증가에 따라 위암발생의 감소가 관찰되었고 제 6군에서는 제 3군보다 암발생이 억제되었다. 그러나 제 4군에서는 제 3군보다 상회하는 발암율을 보였다. 3. 위의 양성병변은 재생성 과증식, 선종성 과증식, 섬유 증식증 등이었고 MNNG 투여 각 우유사료군간의 분포는 우유농도 증가에 따라 위 양성병변이 증가하였으며 특히 암 수반율이 작은 재생성 과증식 발생군에서 뚜렷하였다. 재생성 과증식군에서의 암 수반율은 22.2%, 선종성 과증식군에서는 57.9%로 유의한 차이를 보였다(p<0.05). 4. 소장암 발생은 위암에서와 같이 십이지장의 선암이 주이었고 종양 발생 빈도는 3군에서 5%, 4군에서 21.1%, 5군에서 22.2%, 6군에서 9.5%이었으나 발생예수가 작아 각 군간의 통계적 유의성은 없었다. 5. 혈중가스트린치는 암발생이 많았던 제 4군에서 증가되었고(p<0.01), 양성 위 병변과 관련된 혈중 가스트린치도 제 4군에서 증가하였으며, 특히 재생성 과증식 수반동물군에서의 가스트린 증가는 유의하였으며(p<0.05), 위암발생군에서도 가스트린이 유의한 증가를 보였다(p<0.05). 이상의 성적을 바탕으로 위암발생은 우유농도 증가에 따라 감소되며 고농도의 우유사료군에서 발생이 억제되고 있음은 전암성 병변으로부터의 암발생을 억제하려는 우유의 암 발생 지연효과인 것 같다. 저농도 우유사료군에서의 암발생율의 증가는 혈중 가스트린치의 증가가 그 한 요인으로 해석되며 암발생군에서의 가스트린치의 증가와 더불어(p<0.05) 전암성 병변인 재생성 과증식군에서의 가스트린 증가가(p<0.05) 이를 뒷받침하고 있다.

• 대한본초학회지
• /
• 제24권3호
• /
• pp.1-12
• /
• 2009

Objectives : The objective of this study was to compare, the potency of toxicity of Cantharidin containing dried Mylabis phalerata (MP) extract and it's modifier. Methods ： They were monitored at dosage level 2,000, 1,000, 500, 250 and 125 mg/kg, respectively. Changes of body weight, clinical signs, mortality, LD50, macroscopic changes of gastrointestinal tract and liver were observed after single oral dose of test articles with changes of serum Gastrin and Somatostatin levels. Results ： Dosage-dependent decrease of body weight and/or gains were demonstrated in dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, the body weights were significantly increased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently detected clinical signs in dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these clinical signs dramatically were decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependent increase of mortality rates were observed in dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, the mortalities were significantly decreased compared to that of equal dosage group of dried MP extract-dosing group. The LD50 of dried MP extract in male mice was dramaticlly increased in their modify, 265.86 vs 426.99 mg/kg. Dosage-dependently increase of number of hemorrhagic and/or erythematous spots detected in the gastrointestinal tracts of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal spots were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently increase of degrees of enlargement and congestion detected in the liver of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal signs were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently increase of serum gastrin levels of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal increase were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently increase of serum somatostatin levels of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal increase were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Conclusions ： The toxicity of dried MP extract was reduced by their modify.

• 대한방사성의약품학회지
• /
• 제3권2호
• /
• pp.59-64
• /
• 2017

It has been reported that $^{64}Cu$ was radiolabeled with bombesin (BBN) peptide binding to the gastrin releasing peptide receptor expressed in human prostate cancer cells (PC3), confirming tumor target efficacy in mouse model. In this study, we developed the kit for the diagnosis and treatment of prostate cancer that can be used clinically using bombesin peptide available of $^{64}Cu$ and $^{177}Lu$ radioisotope labeling. The NODAGA-galacto-BBN peptide containing the NODAGA chelator and galactose was dispensed into a sterilized glass vial and lyophilized to prepare a kit. The stability of the kit after long-term storage in the $4^{\circ}C$ cold chamber and the radiolabeling efficiency after $^{64}Cu$ or $^{177}Lu$ labeling were confirmed by thin layer chromatography. When labeling with $^{64}Cu$ at the initial stage of storage, labeling efficiency of NODAGA-galacto-BBN peptide kit was over 96%, labeling efficiency was over 90% when $^{177}Lu$ was labeled. At 11 months after storage, the radiolabeling efficiency of kit against $^{64}Cu$ and $^{177}Lu$ was each over 95% and 90%. The cell viability was significantly reduced in the $^{177}Lu$-NODAGA-galacto-BBN treated group compared with the control and $^{177}Lu$ alone treated group in clonogenic assay. In conclusion, the NODAGA-galacto-BBN kit prepared by the lyophilization showed high stability over time and high yield of radioisotope labeling. Also $^{177}Lu$-NODAGA-galacto-BBN confirmed high cytotoxicity to prostate cancer cells. Therefore, the NODAGA-galacto-bombesin kit is expected to be useful for the diagnosis and treatment of prostate cancer patients.

• The Korean Journal of Physiology
• /
• 제24권2호
• /
• pp.363-375
• /
• 1990

The present investigation was performed to purify bombesin-like immunoreactivity (BBS-LI) from the skin of frogs, B. orientalis inhabiting Korea. For extraction of BBS-LI, the fresh skin of 360 g from frogs was immersed in 1,800 ml of 100% methanol and then kept at $4^{\circ}C$ for 5 days. BBS-LI was partially purified by liquid chromatography using an alkaline alumina column followed by a Sephadex G-10 column. BBS-LI was further purified by using sequential HPLC of reversed phase C18 preparation, gel permeation, SP-ion exchange and reversed phase C18 analysis. BBS-LI in fractions of each step was monitored by radioimmunoassay for which bombesin antiserum with a titer of 1 : 188,800 was raised in a guinea pig. Eventually, two different BBS-LI were successfully purified and each BBS-LI showed the following character. 1) BBS-LI was well separated into two peaks in SP-ion exchange HPLC. One (BBS-LI-K1) bound to the column while the other (BBS-LI-K2) did not. 2) BBS-LI-K1, 73.8% of total BBS-LI, was not differentiated from synthetic bombesin in reversed phase C18 analytical and gel permeation HPLC. 3) BBS-LI-K2, 26.2% of total BBS-LI, eluted later than synthetic bombesin in reversed phase C18 analytical HPLC, but it eluted with a retention time identical to that of synthetic bombesin in gel permeation HPLC. 4) The two forms of BBS-LI and synthetic bombesin identically stimulated gastrin release and pancreatic exocrine secretion including volume, protein output and amylase output in anesthetized rats. It is concluded from the above results that the skin of B. orientalis contains two different forms of BBS-LI which are very identical to bombesin immunologically and biologically. In comparison with synthetic bombesin containing 14 amino acid residues, the major form shows quite similar pattern in all HPLC used in the present study, but the minor form exhibits quite different pattern in SP-ion exchange and reversed phase C18 analytical HPLG.

• Laboraroty Animal Research
• /
• 제34권4호
• /
• pp.223-231
• /
• 2018

Regulation of gastrointestinal hormones have been reported in animal models for constipation undergoing laxative therapy when administered herbal products. We undertook to investigate whether the laxative activity of gallotannin-enriched extracts isolated from Galla Rhois (GEGR) affects the regulation of gastrointestinal hormones, by examining the concentration of four hormones and the activation of their receptors in the loperamide (Lop)-induced constipation model. Stool parameters, including number, weight and water content, were significantly recovered in the Lop+GEGR treated group, relative to the Lop+ vehicle treated group; however, food intake and water consumption were maintained at a constant level. Also, a similar recovery was detected for thickness of mucosa, muscle and flat luminal surface in the Lop+GEGR treated group. Furthermore, concentration of the four gastrointestinal hormones evaluated, namely, cholecystokinin (CCK), gastrin (GAS), somatostatin (SS) and motilin (MTL), were lower in the Lop+vehicle treated group than the No treated group, but were remarkably enhanced in the Lop+GEGR treated group. Moreover, the downstream signaling pathway of MTL and SS receptors were recovered after GEGR administration. Results of the present study therefore indicate that the laxative effects of GEGR treatment may be tightly related with the regulation of gastrointestinal hormones in the Lopinduced constipation model.

• 한국식품위생안전성학회지
• /
• 제32권6호
• /
• pp.536-541
• /
• 2017

본 연구는 까마귀쪽나무열매추출물(LJF-HE)이 흰쥐모델에서 스트레스로 유발되어지는 위염에 대한 억제효과를 확인하고자 하였다. 이때 까마귀쪽나무열매추출물(LJF-HE)소재는 지표성분인 hamabiwalactone B의 함량이 $15.23{\pm}0.057mg/g$로 규격에 적합한 것을 사용하였다, 동물실험에 있어 군분리는 정상군(normal), 양성 대조군(control, 수침 구속 스트레스 위염 유발), 약물 대조군(ranitidine, 50 mg/kg), 까마귀쪽나무열매추출물 저농도 투여군(LJF-HE-L, 30 mg/kg), 까마귀쪽나무열매추출물 중농도 투여군(LJF-HE-M, 60 mg/kg), 까마귀쪽나무열매추출물 고농도 투여군(LJF-HE-H, 120 mg/kg)의 총 6군으로 구성하여 실험을 진행하였다. 그 결과 까마귀쪽나무열매추출물의 투여그룹(LJF-HE-L, LJF-HE-M, LJF-HE-H)에서 염증의 길이가 control 그룹에 비하여 통계적으로 유의하게 감소하였으며, 육안 병변 관찰에서도 까마귀쪽나무열매추출물(LJF-HE) 투여그룹에서의 위 염증과 점막출혈 부위가 control 그룹에 비하여 감소하였음을 관찰할 수 있었다. 또한 까마귀쪽나무열매추출물(LJF-HE) 투여그룹에서의 펩신 활성도도 control 대비 유의성 있게 감소하는 것으로 나타나 까마귀쪽나무 열매추출물은 펩신 활성도를 낮춰 위염 발생을 억제하는 것으로 사료된다. 그리고 까마귀쪽나무열매추출물의 투여 그룹(LJF-HE-M, LJF-HE-H)에서 gastrin에 의해 활성화 되는 CCK-2r 유전자 발현이 대조군에 비해 유의적으로 억제되는 것으로 나타났으며, 염증성 cytokine중에 하나인 IL-$1{\beta}$의 혈장 내 함량이 대조군에 비해 유의적으로 감소하였고, 세포보호물질로 점액 및 혈류량을 증가시켜 위점막을 보호하는 역할을 하는 PGE2의 혈장 내 함량이 대조군에 비해 유의적으로 증가한 결과를 얻었다. 이와 같은 결과는 까마귀쪽나무열매추출물(LJF-HE)이 스트레스로 유발되어지는 위염에 대한 억제효과가 있음을 확인하였다.